Biosceptre International Limited
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel prize-winning science leadership and renowned researchers, our work is founded on science from the University of Sydney, Australia. Biosceptre is headquartered in the UK and has research underway in both Sydney and Cambridge, UK. Our pioneering team discovered the oncology target nfP2X7 – which is shown to be present on the cell surface of a wide range of tumour types, including lung, breast, colorectal and prostate. As the leaders in this area, we currently have several nfP2X7-focused programs approaching clinical stage that, if successful, have the potential to deliver real improvements to outcomes for millions of cancer patients worldwide.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
Supported by the ongoing collaboration with global experts and major research institutes, Biosceptre continues to drive innovation and pioneer the future of nfP2X7-targeted oncology therapeutics.
A Promise Beyond Cancer
Envisioning the future of targeted therapeutics
Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Focused on cell therapy and immune-oncology treatment, we are committed to improving the lives of millions of patients across the world who are suffering from a wide range of malignancies.
Innovation
Inspired and ambitious, our researchers are pioneers in cancer research having made, what we believe to be one of the most exciting advances in targeted therapies, the discovery of nfP2X7 – a new oncology target which is shown to be present on the cell surface of a wide range of cancers, including lung, breast, colorectal and prostate.
We have several chimeric antigen receptor (CAR) T-cell and antibody programs in development that focus on nfP2X7 and, if successful, are one step closer to our vision of best-in-class targeted treatment for a great number of cancer patients.